TVRD

• 2026-05-08 share offering or dilution eventrecentOpen filing ↗
  “…or liabilities as of March 31, 2026 and December 31, 2025. There were no transfers between Levels during the periods presented.…”
  +1 more passage from the same document

  • “…the periods presented. The unrealized loss on the Company’s short-term investments for the three months ended March 31, 2026 and the…”
• 2026-05-08 merger or acquisition eventrecentOpen filing ↗
  “…trial of TTI-101 in idiopathic pulmonary fibrosis (IPF) and concluded that the study did not meet its goals. The Company is…”
  +1 more passage from the same document

  • “…anticipated in these forward-looking statements as a result of various factors. Factors that could cause or contribute to these…”
• 2026-05-01 capital return (buybacks/dividends)recentOpen filing ↗
  “…Warrants ​ From time to time, we may offer and sell up to $200,000,000 of any combination of shares of our common stock, shares…”
• 2026-05-01 merger or acquisition eventrecentOpen filing ↗
  “…We were originally incorporated in Delaware in July 2004 as Cara Therapeutics, Inc. (“Cara”). On April 15, 2025 (the “Closing…”
  +1 more passage from the same document

  • “…Inc. (“Cara”). On April 15, 2025 (the “Closing Date”), Cara, now known as Tvardi Therapeutics, Inc., completed its previously…”
• 2026-05-01 reverse splitrecentOpen filing ↗
  “…which Merger Sub merged with and into Legacy Tvardi, with Legacy Tvardi surviving the merger as a wholly owned subsidiary of Cara…”
  +1 more passage from the same document

  • “…Tvardi, with Legacy Tvardi surviving the merger as a wholly owned subsidiary of Cara (the “Merger”). Also on April 15, 2025, Cara…”

Recorded SEC filings in plain language — not advice or a prediction.